Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma - PubMed
8 days ago
- #CAR T-cell therapy
- #Bruton tyrosine kinase inhibitor
- #Mantle cell lymphoma
- Ibrutinib exposure improves efficacy of CAR T-cell therapy (brexu-cel) in relapsed/refractory mantle cell lymphoma (MCL).
- Ibrutinib-exposed patients showed better progression-free survival, greater CAR T-cell expansion, and more toxicity compared to acalabrutinib-exposed patients.
- Ibrutinib-treated patients had increased T helper 17 cells and cytotoxic transcriptional signatures in CAR T cells.
- CAR T cells from ibrutinib-exposed patients exhibited effector memory differentiation, correlating with clinical response.
- Acalabrutinib-treated patients' CAR T cells showed central memory phenotypes and less effector differentiation.
- BTKi exposure (ibrutinib vs. acalabrutinib) is a significant variable affecting CAR T-cell therapy outcomes in MCL.